ESG Report 2021

As of 31 December 2021, the Group had a total of and the corresponding stages of research and 23 generic drugs and new drug projects under development are as shown above (Major R&D research, including 10 chemical drugs and 13 Pipeline). It is expected that these products will lay a biological products, 1 of which was pending good foundation for the Group's sustainable approval for production and 3 were in clinical stage, development in its future operations. 2 were pending clinical approval, and 17 were in the On the basis of excellent product quality, production preclinical stage. In addition, the Group actively process and production equipment, the Group responded to the national Quality and Efficacy actively seeks breakthroughs and creates benefits. Consistency Evaluation of Generic Drugs, and We have successfully achieved a number of carried out a consistency evaluation study for scientific research results, not only providing more multiple injection generic drugs, with 18 consistency high-quality pharmaceutical products to the public, evaluation projects that were in progress. The Group but also improving the Group's operation and currently has a variety of key research and production efficiency. development products. The product treatment areas The Group has made significant progress in the improving blood glucose control, reducing research and development of diabetic medicines. hypoglycemia risks and improving compliance, and is ® ® The United Laboratories USLIN UBLIN insulin aspart more suitable for high-risk patients with impaired injection and insulin aspart 30 injection have been awareness of hypoglycemia (IAH). approved for marketing by the National Medical Based on the research of the above drugs , the Products Administration (NMPA). Insulin aspart is a third generation insulin analogue product and is a Group ' s application for insulin aspart 50 injection fast-acting drug for the treatment of diabetes. has also successfully obtained the approval from the Compared with soluble human insulin, insulin aspart NMPA to commence clinical trials for diabetes . has a rapid onset of action and a high safety profile, GLP - 1 receptor agonist-Semaglutide injection which can significantly improve the postprandial received the notice of acceptance of clinical trial blood glucose level, and is a relatively important application . The Group will continue to explore anti - meal-time insulin in diabetes treatment. The insulin diabetic drugs to benefit diabetes patients and aspart 30 injection is a pre-mixed insulin analogue make contributions to the management of diabetes consisting of 30% soluble insulin aspart and 70% treatment in China . glargine insulin aspart. It has obvious advantages in Research and Development Achievements of Diabetes Drugs The product research and development of The Quality and Efficacy Evaluation for Generic Drugs, United Laboratories strictly follows the national laws while Tenofovir Disoproxil Fumarate tablets obtained and regulations on pharmaceutical products and the the drug registration certificate and was deemed to technical guidance principles. The scientific research have passed the Consistency of Quality and Efficacy team conducts sufficient research on the Evaluation for Generic Drugs. A number of products pharmaceutical quality and bioequivalence of have passed the consistency evaluation of generic pharmaceutical products in combination with the drugs, which gradually enhanced the Group's technical requirements of drug marketing application competitive advantages in the market. Up to now, a and generic drug consistency evaluation to ensure total of six products of the Group have passed that the drugs meet the requirements of safety, (including deemed passed) the Consistency effectiveness and quality control. Evaluation. The Group will continue to promote the consistency evaluation of generic drugs to provide During the Year, the Group's glipizide tablets and patients with more choices of high-quality drugs. amoxicillin capsules passed the Consistency of Multiple Products Passed the Consistency Evaluation 19 Environmental, Social and Governance Report 2021 The United Laboratories International Holdings Limited